Should I buy or sell Ipsen stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPSEY shares. View IPSEY analyst ratings or view top-rated stocks .

How have IPSEY shares performed in 2024?

Ipsen's stock was trading at $29.48 at the beginning of 2024. Since then, IPSEY stock has decreased by 2.5% and is now trading at $28.7550. View the best growth stocks for 2024 here .

Are investors shorting Ipsen?

Ipsen saw a increase in short interest in March. As of March 31st, there was short interest totaling 500 shares, an increase of 25.0% from the March 15th total of 400 shares. Based on an average daily trading volume, of 1,200 shares, the days-to-cover ratio is presently 0.4 days. View Ipsen's Short Interest .

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen declared a dividend on Thursday, June 1st. Shareholders of record on Monday, June 5th will be paid a dividend of $0.2337 per share on Tuesday, June 27th. This represents a dividend yield of 0.8%. The ex-dividend date is Friday, June 2nd. This is an increase from the stock's previous dividend of $0.23. Read our dividend analysis for IPSEY .

Is Ipsen a good dividend stock?

Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.80%. Read our dividend analysis for IPSEY .

How do I buy shares of Ipsen?

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:IPSEY

Ipsen (IPSEY) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free IPSEY Stock Alerts

$28.76

+0.04 (+0.14%)

(As of 04/19/2024 ET)

Compare

Today's Range: $28.76
▼
$28.76
50-Day Range: $27.50
▼
$30.34
52-Week Range: $26.97
▼
$34.34

Volume: 1,330 shs
Average Volume: 2,148 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 0.80%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Dividend Headlines Short Interest

Get Ipsen alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Ipsen Stock (OTCMKTS:IPSEY)

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

IPSEY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IPSEY Stock News Headlines

April 17, 2024 | finance.yahoo.com

Ipsen publishes its 2023 Universal Registration Document

April 5, 2024 | seekingalpha.com

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

April 20, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 2, 2024 | finance.yahoo.com

Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen

February 15, 2024 | globenewswire.com

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

February 14, 2024 | financialpost.com

Ipsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

February 13, 2024 | finance.yahoo.com

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

February 13, 2024 | msn.com

Ipsen gets FDA approval for pancreatic cancer drug regimen

April 20, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 8, 2024 | marketwatch.com

Ipsen Shares Fall After Forecast of Lower Margin

February 8, 2024 | markets.businessinsider.com

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

February 8, 2024 | markets.businessinsider.com

Ipsen FY23 Profit Flat, Sales Rise; Sees Growth In FY24, Backs Mid-term View

February 8, 2024 | msn.com

Ipsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlook

February 6, 2024 | finance.yahoo.com

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

January 31, 2024 | markets.businessinsider.com

Biotech Stocks Facing FDA Decision In February 2024

January 22, 2024 | finanznachrichten.de

Ipsen Pharma: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

January 22, 2024 | finance.yahoo.com

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

December 7, 2023 | markets.businessinsider.com

Ipsen : FDA Grants Priority Review To Elafibranor NDA For Rare Cholestatic Liver Disease Treatment

December 7, 2023 | finance.yahoo.com

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

November 13, 2023 | markets.businessinsider.com

Ipsen Says Health Canada Approved Bylvay To Treat Pruritus Due To PFIC

November 13, 2023 | finance.yahoo.com

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

October 26, 2023 | nasdaq.com

Ipsen 9-month Sales Up

October 23, 2023 | markets.businessinsider.com

Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome

October 3, 2023 | finanznachrichten.de

Ipsen Pharma: Ipsen updates on QM-1114 regulatory process

October 3, 2023 | finance.yahoo.com

Ipsen updates on QM-1114 regulatory process

September 28, 2023 | fortune.com

Laura Ipsen

September 17, 2023 | msn.com

Ipsen celebrates 75 years of its location in Cherry Valley

See More Headlines

Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: N/A
Current Symbol: OTCMKTS:IPSEY
CUSIP: N/A
CIK: N/A
Web: www.ipsen.com
Phone: (315) 833-5000
Fax: 33-01-58-33-50-01
Employees: 5,300
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.17
Quick Ratio: 0.99

Sales & Book Value

Annual Sales: $3.58 billion
Price / Sales: N/A
Cash Flow: $3.53 per share
Price / Cash Flow: 8.15
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.92

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. David Loew (Age 57)
MD, CEO & Director
Comp: $2.36M
Mr. Aymeric Le Chatelier (Age 55)
Executive VP & CFO
Comp: $776.95k
Dr. Aidan Murphy Ph.D. (Age 58)
Executive VP and Head of Technical Operations
Mr. Craig Marks
Vice-President of Investor Relations
Mr. Francois Garnier (Age 62)
Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer
Ms. Gwenan White
Executive VP and Head of Communications, Public Affairs & Sustainability
Mr. Regis Mulot (Age 58)
Executive VP & Chief Human Resources Officer
Ms. Dominique Bery (Age 53)
Head of Nordics & Baltics
Mr. Bartosz Bednarz D.D.S.
Executive VP and Head of Global Product & Portfolio Strategy
Mr. Philippe Lopes-Fernandes CBO
Executive VP & Chief Business Officer

Key Competitors

View All Competitors

IPSEY Stock Analysis - Frequently Asked Questions

Should I buy or sell Ipsen stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPSEY shares.
View IPSEY analyst ratings or view top-rated stocks.
How have IPSEY shares performed in 2024?: Ipsen's stock was trading at $29.48 at the beginning of 2024. Since then, IPSEY stock has decreased by 2.5% and is now trading at $28.7550.
View the best growth stocks for 2024 here.
Are investors shorting Ipsen?: Ipsen saw a increase in short interest in March. As of March 31st, there was short interest totaling 500 shares, an increase of 25.0% from the March 15th total of 400 shares. Based on an average daily trading volume, of 1,200 shares, the days-to-cover ratio is presently 0.4 days.
View Ipsen's Short Interest.
How often does Ipsen pay dividends? What is the dividend yield for Ipsen?: Ipsen declared a dividend on Thursday, June 1st. Shareholders of record on Monday, June 5th will be paid a dividend of $0.2337 per share on Tuesday, June 27th. This represents a dividend yield of 0.8%. The ex-dividend date is Friday, June 2nd. This is an increase from the stock's previous dividend of $0.23.
Read our dividend analysis for IPSEY.

Is Ipsen a good dividend stock?: Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.80%.
Read our dividend analysis for IPSEY.
How do I buy shares of Ipsen?: Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IPSEY) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial